30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).
30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations
30 TECHNOLOGY: DELIVERING THE FULL POTENTIAL OF THERAPEUTIC NITRIC OXIDE
30 TECHNOLOGY is developing nitric oxide-generating technologies
for a range of health care applications